Cathay Biotech (688065): Revenue growth driven by increased production of long-chain dicarboxylic acids; downstream applications of bio-based new materials accelerating commercialization

Event: On April 24, 2026, Cathay Biotech released its 2025 annual report, disclosing revenue of RMB 3.295 billion for 2025, an increase of 11.40% year-over-year; net profit attributable to shareholders amounted to RMB 561 million, up

Great Wall SecuritiesMay 28 18:42

Company Q&A | Kaisai Bio: Bio-based polyamides are still in the commercial promotion stage. The company is accelerating capacity utilization through various measures such as expanding application scenarios and deepening customer cooperation.

Gelonghui, May 13 | An investor asked Kaisai Bio on an interactive platform: It was noted that the company's net profit attributable to shareholders in 2025 is expected to increase by 14.68%, while the net operating cash flow has dropped by 50.77%. What are the specific reasons for this and will it be a continuing trend? Additionally, the gross margin of the bio-based polyamide series remains negative (-14.69%), with a capacity utilization rate of only 9.2%, yet the company continues to expand production with construction-in-progress amounting to 6.6 billion yuan. When will this business reach the break-even point? Does the large-scale expansion pose risks of impairment? Kaisai Bio responded that its main business operations in 2025 will continue to grow, driving increases in sales revenue and gross profit.

Gelonghui FinanceMay 13 17:44

Company Q&A | Kaysi Bio: The company’s EX700 ultra-long chain polyamide product is actively advancing towards commercial implementation and has already achieved mass production in the areas of commercial vehicle brake lines and energy storage box cooling.

Gelonghui, May 13th | An investor asked Kaisai Bio on an interactive platform: According to the introduction at your company's booth, EX700 ultra-long-chain polyamide can precisely meet the requirements of AI data cooling, thermal management for the three electric systems in new energy vehicles, chassis air suspension, cooling and fire prevention for energy storage boxes, and high-temperature braking pipelines for commercial vehicles. It is also widely used in consumer electronics and 3D printing. Could you introduce the commercialization progress in these areas? Which companies have started sample submission and certification? Kaisai Bio replied that its EX700 ultra-long-chain polyamide product is actively promoting commercial implementation in commercial vehicle braking pipelines.

Gelonghui FinanceMay 13 17:41

Company Q&A | Kaisai Bio: The fields of hydrogen storage and transportation, as well as liners for hydrogen storage tanks, are among the key application directions for the company's high-performance thermoplastic bio-based composite materials. The company

Gelonghui, May 13 | An investor asked Kaisai Bio on an interactive platform: Could you please provide an update on the development and commercialization progress of your hydrogen transport pipelines and the liners for the fourth-generation hydrogen storage tanks? What certifications have been obtained? What is the status of sample certification with relevant companies? Kaisai Bio replied that the fields of hydrogen storage and transportation, as well as liners for hydrogen storage tanks, represent one of the key application areas for the company’s high-performance thermoplastic bio-based composite materials. The company has completed the initial sample preparation and is now advancing iterative technology development and industrial ecosystem integration in alignment with product performance characteristics and the needs of the hydrogen energy industry. For specific updates and certification details, please refer to the company's official announcements.

Gelonghui FinanceMay 13 17:16

Cathay Biotech (688065): Growth in production and sales of long-chain dicarboxylic acids; bio-based materials expected to scale up significantly.

Event Description: On April 24 and April 30, the company released its 2025 annual report and Q1 2026 report, respectively. In 2025, the company achieved a total operating revenue of 3.295 billion yuan, representing a year-on-year increase of 11.40%; net profit attributable to...

Huaan SecuritiesMay 13 07:27

With annual revenue exceeding 3 billion yuan, is Kaisai Bio (688065.SH) a truly scarce investment target?

In 2025, Kaisai Bio achieved a breakthrough in annual operating revenue, surpassing 3 billion yuan.

Zhitong FinanceMay 9 15:58